Updates

** Dr Reddy's Laboratories REDY.NS closed 1.8% down at 1246.5 rupees, down as much as 3.7% in the session

** Stock logs second straight day of losses; down 9.3% over the week, biggest weekly drop since May 2023

** Co reported on Thursday that supplies of generic semaglutide would remain unavailable in India and face disruptions in Canada due to impurities in API, until late October at least

** Systematix downgrades REDY to "hold", believes execution risk remains, with possibility of further delays

** Emkay Global ("reduce", PT 1,300 rupees) cuts FY27 earnings estimates by 7% as prior margin assumptions "now seem out of reach"

** REDY rated "hold" on avg by 38 analysts; median PT 1,300 rupees - data compiled by LSEG

** Torrent Pharmaceuticals TORP.NS, which sources finished semaglutide doses from REDY, down 2.3%

** REDY down 2% YTD